Skip to content

Study · Non-randomized trial · n = 23 · 2006

7 results

Preoperative treatment of uterine leiomyomas: clinical findings and expression of transforming growth factor-beta3 and connective tissue growth factor.

De Falco M, Staibano S, D'Armiento FP, Mascolo M, Salvatore G, Busiello A, Carbone IF, Pollio F, Di Lieto A

Journal of the Society for Gynecologic Investigation1 May 2006Cited by 27 (Europe PMC)

PMID16697947 (opens in a new tab)DOI10.1016/j.jsgi.2006.02.008 (opens in a new tab)PepBankPUB-16697947
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with uterine leiomyomas, hemoglobin increased after leuprolide treatment.

    In plain wordsHemoglobin increased after leuprolide treatment in patients with uterine fibroids.

    Peptide
    Leuprolide
    Outcome
    IncreaseHemoglobin
    Study

    n = 23

    Outcome group
    Hematologic parameters · Whole body
    Studied dose
    3.75 mg depot · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    After therapy, hemoglobin and iron levels similarly increased in both groups.
    1 context sentence
    Summary · context
    Twenty-three patients received 3.75 mg leuprolide acetate depot for 4 months.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with uterine leiomyomas, iron levels increased after leuprolide treatment.

    In plain wordsIron levels increased after leuprolide treatment in patients with uterine fibroids.

    Peptide
    Leuprolide
    Outcome
    IncreaseIron
    Study

    n = 23

    Outcome group
    Hematologic parameters · Whole body
    Studied dose
    3.75 mg depot · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    After therapy, hemoglobin and iron levels similarly increased in both groups.
    1 context sentence
    Summary · context
    Twenty-three patients received 3.75 mg leuprolide acetate depot for 4 months.
  3. 03HumanNon-randomized trialSafety outcome

    In patients with uterine leiomyomas, bone mineral density significantly decreased after leuprolide alone.

    In plain wordsBone density decreased significantly after leuprolide alone in patients with uterine fibroids.

    Peptide
    Leuprolide
    Outcome
    DecreaseBone mineral density
    Study

    n = 23

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    3.75 mg depot · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    BMD significantly decreased only in the GnRH-a group.
    1 context sentence
    Summary · context
    Twenty-three patients received 3.75 mg leuprolide acetate depot for 4 months.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with uterine leiomyomas, uterine volume decreased after leuprolide treatment.

    In plain wordsUterine volume decreased after leuprolide treatment in patients with uterine fibroids.

    Peptide
    Leuprolide
    Outcome
    DecreaseUterine volume
    Study

    n = 23

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.75 mg depot · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    Uterine volume similarly decreased in both groups.
    1 context sentence
    Summary · context
    Twenty-three patients received 3.75 mg leuprolide acetate depot for 4 months.
  5. 05HumanNon-randomized trialEfficacy outcome

    In patients with uterine leiomyomas, no patient had menorrhagia at the end of leuprolide treatment.

    In plain wordsNo patient with uterine fibroids had heavy menstrual bleeding at the end of leuprolide treatment.

    Peptide
    Leuprolide
    Outcome
    Direction not reportedMenorrhagia
    Study

    n = 23

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.75 mg depot · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    No patient had menorrhagia or pelvic pain at the end of therapy.
    1 context sentence
    Summary · context
    Twenty-three patients received 3.75 mg leuprolide acetate depot for 4 months.
  6. 06HumanNon-randomized trialEfficacy outcome

    In patients with uterine leiomyomas, no patient had pelvic pain at the end of leuprolide treatment.

    In plain wordsNo patient with uterine fibroids had pelvic pain at the end of leuprolide treatment.

    Peptide
    Leuprolide
    Outcome
    Direction not reportedPelvic pain
    Study

    n = 23

    Outcome group
    Pain · Reproductive and sexual health
    Studied dose
    3.75 mg depot · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    No patient had menorrhagia or pelvic pain at the end of therapy.
    1 context sentence
    Summary · context
    Twenty-three patients received 3.75 mg leuprolide acetate depot for 4 months.
  7. 07HumanNon-randomized trialSafety outcome

    In patients with uterine leiomyomas, hot flushes increased after the first month of leuprolide alone.

    In plain wordsHot flushes increased after the first month of leuprolide alone in patients with uterine fibroids.

    Peptide
    Leuprolide
    Outcome
    IncreaseHot flushes
    Study

    n = 23

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    3.75 mg depot · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    The number of hot flushes increased after the first month in the GnRH-a group;
    1 context sentence
    Summary · context
    Twenty-three patients received 3.75 mg leuprolide acetate depot for 4 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.